Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.

Background: Immune checkpoint inhibitors (ICIs) treatment have shown high efficacy for about 15 cancer types. However, this therapy is only effective in 20-30% of cancer patients. Thus, the precise biomarkers of ICI response are an urgent need.

A New Approach of Detecting Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis.

Background: In clinical practice, various methods are used to identify gene rearrangements in tumor samples, ranging from "classic" techniques, such as IHC, FISH, and RT-qPCR, to more advanced highly multiplexed approaches, such as NanoString technology and NGS panels. Each of these methods has its own advantages and disadvantages, but they share the drawback of detecting only a restricted (although sometimes quite extensive) set of preselected biomarkers. At the same time, whole transcriptome sequencing (WTS, RNAseq) can, in principle, be used to detect gene fusions while simultaneously analyzing an incomparably wide range of tumor characteristics.

Scalable Slot-Die Coating of Passivation Layers for Improved Performance of Perovskite Solar Cell Modules.

Upscaling the perovskite solar cell (PSC) while avoiding losses in the power conversion efficiency presents a substantial challenge, especially when transitioning from ≤1 cm cells to ≥10 cm modules. In addition to the fabrication of key functional layers, scalable technologies for surface passivation, considered indispensable for achieving high-performance PSCs, are urgently required. However, studies on this topic remain limited.

Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming promoter methylation.

Background: Glioblastoma (GBM) is the most aggressive and lethal central nervous system (CNS) tumor. The treatment strategy is mainly surgery and/or radiation therapy, both combined with adjuvant temozolomide (TMZ) chemotherapy. Historically, methylation of gene promoter is used as the major biomarker predicting individual tumor response to TMZ.

Number of human protein interactions correlates with structural, but not regulatory conservation of the respective genes.

Introduction: The differential ratio of nonsynonymous to synonymous nucleotide substitutions (dN/dS) is a common measure of the rate of structural evolution in proteincoding genes. In addition, we recently suggested that the proportion of transposable elements in gene promoters that host functional genomic sites serves as a marker of the rate of regulatory evolution of genes. Such functional genomic regions may include transcription factor binding sites and modified histone binding loci.